2023
HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC).
Jeon J, Chen K, Madison R, Schrock A, Sokol E, Levy M, Oxnard G, Huang R, Pusztai L. HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC). Journal Of Clinical Oncology 2023, 41: 539-539. DOI: 10.1200/jco.2023.41.16_suppl.539.Peer-Reviewed Original ResearchEarly-stage breast cancerPrimary breast cancerEarly breast cancerBreast cancerStage IHR-/HER2HRR deficiencyPALB2 mutationsEarly-stage primary breast cancerPARP inhibitorsStage IV diseaseHormone receptor statusMonths of diagnosisPositive breast cancerHomologous recombination repairComprehensive genomic profilingHRD signaturesClinical trial dataHigh rateSEER studySomatic BRCAAdjuvant therapyAdvanced diseaseReceptor statusBC subtypes
2020
Association of T- and B-cell receptor repertoires with molecular subtypes and outcome in HER2+ breast cancer: An analysis of the NeoALTTO clinical trial.
Rediti M, Venet D, Rothe F, Qing T, Maetens M, Bradbury I, Izquierdo M, Di Cosimo S, Hilbers F, Bajji M, Harbeck N, Untch M, Liu M, Saura C, Huober J, Nuciforo P, Salgado R, Loi S, Pusztai L, Sotiriou C. Association of T- and B-cell receptor repertoires with molecular subtypes and outcome in HER2+ breast cancer: An analysis of the NeoALTTO clinical trial. Journal Of Clinical Oncology 2020, 38: 511-511. DOI: 10.1200/jco.2020.38.15_suppl.511.Peer-Reviewed Original ResearchPathological complete responseBreast cancerPAM50 subtypesB cell receptorImmune responseBiomarker-driven treatment strategiesTumor-infiltrating lymphocyte levelsBaseline tumor biopsiesEvent-free survivalPhase III trialsAnti-HER2 treatmentGrade 3 tumorsEstrogen receptor statusImproved clinical outcomesProportional hazards modelIII trialsLymphocyte levelsComplete responseReceptor statusClinical outcomesClinicopathological characteristicsBC subtypesClinical trialsTreatment strategiesTumor biopsies
2012
DNA repair metagene signature as a prognostic and predictive factor in molecular breast cancer subtypes.
Santarpia L, Iwamoto T, Di Leo A, Hayashi N, Stampfer M, Guarducci C, Symmans W, Hortobagyi G, Pusztai L, Giampaolo B. DNA repair metagene signature as a prognostic and predictive factor in molecular breast cancer subtypes. Journal Of Clinical Oncology 2012, 30: 1012-1012. DOI: 10.1200/jco.2012.30.15_suppl.1012.Peer-Reviewed Original ResearchPathological complete responseHigher pathological complete responseBreast cancer molecular subtypesTaxane-based regimensTaxane-containing regimensCisplatin-containing regimensMolecular breast cancer subtypesTaxane-based chemotherapyPotential predictive markerBreast cancer subtypesCancer molecular subtypesBC cell linesFalse discovery correctionDistant relapseComplete responseBetter prognosisPoor prognosisPredictive factorsPrognostic valueBC subtypesER-/HER2Predictive markerN patientsPrognostic markerMolecular subtypes
2009
Correlation of PIK3CA mutation-associated gene expression signature (PIK3CA-GS) with deactivation of the PI3K pathway and with prognosis within the luminal-B ER+ breast cancers
Loi S, Haibe-Kains B, Lallemand F, Pusztai L, Bardelli A, Gillett C, Ellis P, Piccart-Gebhart M, Phillips W, McArthur G, Sotiriou C. Correlation of PIK3CA mutation-associated gene expression signature (PIK3CA-GS) with deactivation of the PI3K pathway and with prognosis within the luminal-B ER+ breast cancers. Journal Of Clinical Oncology 2009, 27: 533-533. DOI: 10.1200/jco.2009.27.15_suppl.533.Peer-Reviewed Original ResearchPI3K pathwayBreast cancerPIK3CA mutationsMutation statusGene expression signaturesK pathwayClinical outcomesLuminal B breast cancerLuminal BC subtypePIK3CA mutation statusBetter clinical outcomesIndependent prognostic informationB breast cancerExpression signaturesPI3K inhibitorsPI3K inhibitionBC cohortDistinct gene expression signaturesEndocrine therapyBC samplesBC subtypesPrognostic informationFavorable outcomeEstrogen receptorMutation carriers